Skip to main content
. Author manuscript; available in PMC: 2019 May 3.
Published in final edited form as: Cell. 2018 Apr 5;173(4):958–971.e17. doi: 10.1016/j.cell.2018.03.025

Figure 7. GSK, ISRIB, and Ataxin-2 ASO suppress nucleocytoplasmic transport defects and neurodegeneration in C9-ALS models.

Figure 7

(A) C9-ALS iPSNs treated with DMSO, GSK or ISRIB were stained with Ran (red), MAP2 (green), and DAPI (blue). (B) Control or C9-ALS iPSNs treated with scrambled or Ataxin-2 ASOs were stained with Ran (red), MAP2 (green), and DAPI (blue). Bottom right: ASO-treated C9-ALS iPSNs immunoblotted for Ataxin-2 and β-Actin. (C) Fly salivary glands stained with GFP and DAPI. N: nuclear; W: whole cell. (D) Fly eye degeneration. (E) Flight assay. n numbers in the graph. ns: not significant; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001. Data are represented as mean ± SEM.